埃拉基酸对实验性腐蚀性食道烧伤损伤的作用

相关实验视频

Updated: Jul 2, 2025

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

9.7K

Dilek Aygün Keşim¹, Fırat Aşır², Hayat Ayaz²

¹Department of Physiology, Medical Faculty, Dicle University, Diyarbakır 21280, Turkey.

Current issues in molecular biology

|February 23, 2024

概括

酸 (EA) 通过减少氧化应激和改善腐蚀性损伤后组织再生,促进食道伤口愈合. EA治疗抵消了氧化烧伤的负面影响,增强了恢复.

科学领域:

生物化学生物化学
再生医学是一种再生医学.
毒理学毒理学毒理学

背景情况:

腐蚀性食道烧伤,通常是由氧化 (NaOH) 引起的,在伤口愈合和组织再生方面存在重大挑战.
氧化应激,以MDA水平来表示,在这些损伤的发病过程中起着关键作用.
埃拉基酸 (EA) 是一种已知的抗氧化剂,具有潜在的治疗益处,需要在腐蚀性食道烧伤的背景下进行调查.

研究的目的:

在大鼠模型中研究埃拉基酸 (EA) 对氧化物 (NaOH) 诱导的腐蚀性食道烧伤 (CEB) 的抗氧化和组织再生作用.
阐明EA治疗潜力的基础分子机制,重点关注其相互作用网络和诸如表皮生长因子 (EGF) 等关键介质.

主要方法:

在Wistar白色老鼠中建立一种腐蚀性食道烧伤模型,使用20%的NaOH.
向治疗组口服30毫克/公斤的埃拉基酸 (EA) 给药.
在受伤后28天评估马隆迪阿尔海德 (MDA) 水平,组织病理变化 (缩小,原退化,炎症,纤维化,亡),动物体重和表皮生长因子 (EGF) 表达.

主要成果:

腐蚀性食道烧伤显著增加了MDA含量,组织病理损伤,并降低了动物的体重和EGF表达.
酸 (EA) 治疗显著降低了MDA水平,改善了他的病理学得分,并促进了CEB + EA组的体重增加.
治疗EA可以提高表皮生长因子 (EGF) 的表达,EGF被认为是EA-目标相互作用网络中关键的中介体,对烧伤愈合至关重要.

结论:

埃拉基酸 (EA) 具有显著的抗氧化和组织再生特性,有效地减轻食道腐蚀性烧伤的不良影响.
通过减轻氧化应激和调节关键细胞机制,包括EGF信号传递,EA促进伤口愈合和组织修复.
EA是治疗腐蚀性食道烧伤和增强食道组织再生的有前途的治疗药物.

关键词:

这是NaOH,NaOH.这是一种抗炎药物.抗氧化剂是一种抗氧化剂.腐蚀性物质是一种腐蚀性物质.埃拉基酸是一种酸.

相关概念视频

01:21

Barrett Esophagus-II: Clinical Manifestations and Management

154

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

154

01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...

01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

486

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

486

01:30

Esophageal Strictures-I: Introduction

101

Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...

101

01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...